Overview
International law firm McDermott Will & Emery represented Embecta Corp. (embecta), one of the largest pure-play diabetes care companies in the world, in its partnership with Tidepool, a nonprofit organization harnessing the power of technology to provide intuitive software products that help people with diabetes, to develop an automated insulin delivery (AID) solution for people living with Type 2 diabetes.
embecta will leverage Tidepool’s expertise in diabetes management software to develop the AID algorithm for embecta’s closed-loop patch pump system designed for the specific needs of people living with T2D.
The collaboration was announced on May 12, 2023.
The cross-practice McDermott team was led by Life Sciences co-chair Vernessa Pollard as well as Technology & Outsourcing co-head Shawn Helms, counsel Anisa Mohanty and associate Raja Chatterjee.
Read embecta’s press release here.
McDermott’s Life Sciences Practice includes more than 140 top lawyers with demonstrated strength across every segment of life sciences, including medical devices, biotechnology, diagnostics, digital health and pharmaceuticals. The practice is recognized globally in Chambers USA and Legal 500 2022 as a leader in the life sciences space and represent 75% of the top 20 biopharmaceutical companies worldwide. Additionally, LMG Life Sciences recognized Vernessa Pollard as the “Medical Devices: Regulatory Attorney of the Year.” To learn more, visit https://www.mwe.com/industries/life-sciences/.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
